Change in the Japanese pharmaceutical market: Cradle of innovation or grave of corporate profits?

McKinsey

Insights on Pharmaceuticals & Medical ProductsUnderstanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients.

How Precision Medicine Will Transform the Pharmaceutical and Healthcare Industries

Strategy+Business

And although the pharmaceutical and healthcare industries know this is the way forward, they face some significant hurdles Precision medicine combines business opportunities with clinical health benefits.

What’s behind the pharmaceutical sector’s M&A push

McKinsey

There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios. Strategy & Corporate Finance Insights

Innovating at the speed of the 21st century in pharmaceuticals

McKinsey

The CEO of Eli Lilly offers perspectives on accelerating change in the industry. Our Insights

Building digital ecosystems in Japan

McKinsey

Insights on Pharmaceuticals & Medical ProductsTwo Merck Healthcare digital specialists explain their company’s transformation and the impact it has had on patients.

Why the Pharmaceutical Industry is Booming in Japan - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN

Harvard Business

That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine.

The rise and rise of medtech in Asia

McKinsey

Insights on Pharmaceuticals & Medical ProductsHow can medtech companies thrive in the world’s fastest-growing market?

Genetic testing: Opportunities to unlock value in precision medicine

McKinsey

Insights on Pharmaceuticals & Medical ProductsAdvanced analysis of genomic data integrated with electronic medical records and other data sets, combined with effective reimbursement strategies and full data-regulatory compliance, will distinguish winning diagnostics companies.

Data 83

How new biomolecular platforms and digital technologies are changing R&D

McKinsey

By going digital, biotech pioneers with promising biomolecular platforms are improving drug discovery and development—and changing the pharmaceutical industry. Insights on Pharmaceuticals & Medical Products

Leading change in the Japanese pharma market: Innovating for the future in an uncertain present

McKinsey

Insights on Pharmaceuticals & Medical ProductsJacques Nathan, president of Sanofi Japan, discusses what’s ahead for his changing sector.

Barriers to Digital@Scale: Shifting the focus from tech to culture

McKinsey

Insights on Pharmaceuticals & Medical ProductsMany pharma and medtech companies have a digital strategy. But to pull off a true digital transformation, it's crucial to focus on culture and mindset, according to leaders who attended a recent European roundtable.

R&D in the ‘age of agile’

McKinsey

Insights on Pharmaceuticals & Medical ProductsAs innovation reshapes the pharma landscape, pharma companies will need to revisit their R&D operating models to thrive.

Agile 66

The digital imperative for pharma companies in Japan

McKinsey

Insights on Pharmaceuticals & Medical ProductsFive facts showing that companies should invest in digital customer engagement in Japan.

Digital R&D: The Next Frontier for Biopharmaceuticals

McKinsey

Insights on Pharmaceuticals & Medical ProductsDigital promises to transform R&D productivity over the next decade. What will it take to realize this potential?

Drug Pricing in the United States

Tom Spencer

1 Pharmaceutical companies are unique in their capacity, due to little regulation and oversight, to raise prices. Pharmaceutical companies focus on a variety of factors when pricing drugs with the main objective of generating the most revenue. Topic: Pharmaceutical Industry in the U.S.”

Operations as a competitive advantage in biotechnology

McKinsey

Insights on Pharmaceuticals & Medical ProductsEsteban Santos, executive vice president for operations at Amgen, explains how the company is using operations to support innovation.

Collaborating to address our global public health challenges

McKinsey

Insights on Pharmaceuticals & Medical ProductsJaak Peeters, head of global public health at Johnson & Johnson, discusses the role pharma can play in addressing big challenges, such as fighting diseases like HIV and tuberculosis.

Real-world evidence: Driving a new drug-development paradigm in oncology

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.

The changing face of medical-device design

McKinsey

Insights on Pharmaceuticals & Medical ProductsDesign can help craft a standout patient experience. Here, three leaders discuss how the discipline is improving medical products and driving innovation.

Medical affairs: Key imperatives for engaging and educating physicians in a digital world

McKinsey

Insights on Pharmaceuticals & Medical ProductsFive strategic efforts can help medical affairs teams master customer engagement in the digital age.

From product to customer experience: The new way to launch in pharma

McKinsey

Insights on Pharmaceuticals & Medical ProductsIn increasingly crowded drug markets, a strong clinical profile is no longer enough to ensure a distinctive launch. To be successful, pharma companies need to launch not only products but also experiences.

Asia on the move: Five trends shaping the Asia biopharmaceutical market

McKinsey

Insights on Pharmaceuticals & Medical ProductsEnthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia.

Designing a healthy future for medical devices

McKinsey

Insights on Pharmaceuticals & Medical ProductsDesign is increasingly a business imperative, but medtech companies have been slow to embrace it. What benefits might a focus on medical-device design bring, and how can companies get started?

Five things to know about biosimilars right now

McKinsey

Insights on Pharmaceuticals & Medical ProductsIn the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming months, and how can players set themselves apart?

Launches in oncology: The elements of success

McKinsey

Insights on Pharmaceuticals & Medical ProductsAs the prevalence and severity of cancer has increased, the drug landscape has shifted. Oncology launches are increasingly critical and require a dedicated approach. Here’s what it entails.

Real-world evidence: From activity to impact in healthcare decision making

McKinsey

Insights on Pharmaceuticals & Medical ProductsWhile there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.

How pharma manufacturers can enhance their medical information teams

McKinsey

Insights on Pharmaceuticals & Medical ProductsMedical information teams can be a source of differentiation if used strategically. But the evolving environment means pharma manufacturers will need to make organizational enhancements to get ahead.

What’s next for Japan’s pharma market

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe president of Merck in Japan discusses how healthcare players in the country can capitalize on early detection rates and use collaboration to drive innovation.

The evolving role of medical affairs in Asia?Pacific: Three imperatives for pharmacos

McKinsey

Insights on Pharmaceuticals & Medical ProductsMedical affairs is poised for a broader, more strategic role. However, leaders will need to ramp up new types of capabilities and talent to achieve this ambition.

From semiconductors to life sciences: Building a global business out of Japan

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe president and CEO of JSR Corporation discusses the company’s plans to grow a global healthcare franchise building from his lessons in the semiconductor industry.

3 Business Models That Could Bring Million-Dollar Cures to Everyone

Harvard Business

Innovation Business models Entrepreneurship Healthcare Pharmaceuticals Technology Digital ArticleTEK IMAGE/SCIENCE PHOTO LIBRARY/Getty Images.

Shaking up the value chain

McKinsey

Data and digitization are creating a growing array of value-creation choices in industries as diverse as pharmaceuticals, mining, and energy. Digital Insights

Unleashing the power of entrepreneurship in science

McKinsey

A partner of venture-capital firm Atlas Venture, Bruce Booth, explains how investment assists pharmaceutical innovation. Our Insights

Bringing an animal health business into the fold

McKinsey

Two senior Boehringer Ingelheim executives, Joachim Hasenmaier and Felix Gutsche, discuss the global pharmaceutical company’s deal with Sanofi to acquire its animal health business.

Sexual Harassment Is Rampant in Health Care. Here’s How to Stop It.

Harvard Business

Organizational culture Gender Policy Corporate governance Healthcare Pharmaceuticals Digital ArticleCarmen Martínez Torrón/Getty Images.

Price Gouging and the Dangerous New Breed of Pharma Companies

Harvard Business

For 78-year-old Tony, 3,4 DAP — which can be obtained at low cost from compounding pharmacies or for free through a compassionate-use program supported by a small privately held company, Jacobus Pharmaceuticals — is a lifesaver.

How Japan Is Creating New Opportunities in the Field of Regenerative Medicine - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN

Harvard Business

Regeneratives are pharmaceutical cell therapy products that replace or restore cells and tissues lost to disease or aging. “To be able to do that, they need to entice companies to come to Japan, and they need to entice their own pharmaceutical companies to license in and obtain the best.” It includes a designation system that promotes R&D in Japan aimed at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines.

The One Meeting that Reliably Produces Huge Consulting Projects

David A Fields

There were about fifteen of us—three from my team and a dozen client personnel—in a conference room at the headquarters of one of the world’s largest pharmaceutical companies.

How to succeed as a chief digital officer in pharma

McKinsey

We spoke to ten digital leaders at global pharmaceutical companies to understand how they focus their efforts. The life-sciences industry is embracing digital to unlock innovation. Our Insights

Profile of success: Theranos founder, Elizabeth Holmes

Consultants Mind

Originally, it was catering to pharmaceutical trials … Continue reading → Learning Entrepreneur If you don’t know this company, clearly you are not paying attention. Theranos is a biotechnology start up merging biological systems with information systems. Home healthcare monitoring systems to monitor disease progression in real-time.

How Pharma Companies Game the System to Keep Drugs Expensive

Harvard Business

The 1984 Drug Price Competition and Patent Term Restoration Act gave pharmaceutical companies exclusive protections for innovating a new drug. ” By selling a drug they’re already making under a different name, pharmaceutical firms are effectively extending their monopoly for another six months. Another way pharmaceutical firms are thwarting generics is by restricting access to samples for testing. Regulation Branding Manufacturing Pharmaceuticals Digital Article

How Pharma Can Fix Its Reputation and Its Business at the Same Time

Harvard Business

The business model of research-based pharmaceutical companies is under significant pressure. However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets. citizens than pharmaceuticals (the sector’s worst showing in 16 years). And it is the first topic of the provisional standard for the pharmaceutical sector produced by the Sustainability Accounting Standards Board.

Research: Innovation Suffers When Drug Companies Merge

Harvard Business

This is especially true in pharmaceutical markets where new and affordable drugs can improve and even save the lives of many people. Therefore, pharmaceutical mergers seem to substantially reduce innovation activities in the relevant market as a whole.